USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
NAVIGEN, INC.
Address:
383 Colorow Drive
SALT LAKE CITY, UT 84108
Phone:
N/A
URL:
EIN:
208535861
DUNS:
792046224
Number of Employees:
19
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $3,371,415.00 10
SBIR Phase II $5,392,152.00 3

Award List:

Novel Therapeutic Approach to Acute Lung Injury

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$147,660.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Navigen Pharmaceutical will develop a novel class of protein therapies for treating acute lung injury (ALI)/acute respiratory distress syndrome (ARDS). This work is based on the discovery by our scientific founder, Dean Li, M.D., Ph.D., that there are endogenous… More

Inhibiting pathologic angiogenesis and vascular leak in the eye.

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$140,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): A Navigen founder, Dean Li, MD, PhD, has identified a novel endothelial receptor, Robo4. Robo4 is highly expressed in the retinal endothelium, and activation of this receptor by its endogenous ligand Slit-2 reduces VEG F-induced retinal vascular leak and oxygen… More

Targeting HTRA 1 for the Treatment of Age Related Macular Degeneration

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$146,999.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Age-related macular degeneration (AMD) is the most common cause of visual impairment of the elderly in developed countries. Despite its prevalence with the aging population, its etiology and pathogenesis are poorly unde rstood and the treatment options are… More

Anti-HTRA1 Therapy For AMD

Award Year / Program / Phase:
2009 / SBIR / Phase II
Award Amount:
$1,270,716.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): In our Phase I application, we proposed that blocking HTRA1 with antibodies might be an effective strategy for treating age related macular degeneration. We tested this hypothesis by a) generating monoclonal antibodies against HTRA1 and b) determining whether a… More

Novel Therapeutic Approach to Acute Lung Injury

Award Year / Program / Phase:
2010 / SBIR / Phase II
Award Amount:
$1,121,436.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): In our Phase 1 application, we described an endothelial specific receptor, Robo4, that is expressed in mature vessels and is upregulated following endothelial injury. Robo4, following activation by its protein ligand, S lit2, reduces agonist induced vascular leak… More

SLIT2N for the treatment of influenza-induced acute respiratory distress

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$591,856.00
Agency:
HHS
Principal Investigator:
Elizabeth Wang
Abstract:
DESCRIPTION (provided by applicant): Influenza infection leads to a cytokine storm as the host's immune system fights the virus. This combination of immunity factors has the unfortunate side effect of creating vascular leak. In the case of influenza patien ts, this vascular leak most often occurs in… More

Novel Therapeutic Approach for Sepsis: Blocking the Vascular Response to Cytokine

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$557,531.00
Agency:
HHS
Principal Investigator:
Alan L. Mueller – 801-587-1426
Abstract:
DESCRIPTION (provided by applicant): In the United States alone, sepsis affects approximately 700,000 patients and leads to death of over 210,000 people per year. Sepsis is a clinical syndrome that results from a complex interaction between host and infectious agents, and is characterized by… More

Therapeutic D-peptide Inhibitor of HIV entry

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$299,392.00
Agency:
HHS
Principal Investigator:
Alan L. Mueller – 801-587-1426
Abstract:
DESCRIPTION (provided by applicant): HIV/AIDS remains a formidable global epidemic with 33 million infections worldwide, including over 1 million patients in the US. In 2008, there were 2.7 million new infections and 2 million AIDS-related deaths. CurrentHIV treatment combines drugs from several… More

Protease-resistant D-peptide inhibitors of RSV entry

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$592,068.00
Agency:
HHS
Principal Investigator:
Brett D. Welch – 801-587-1415
Abstract:
DESCRIPTION (provided by applicant): Respiratory syncytial virus (RSV) is the major cause of severe lower respiratory tract infections in children and infants, affecting an estimated 64 million people and causing 160,000 deaths worldwide per year (WHO). Each year in the United States, ~100,000… More

Protease-resistant D-peptide Inhibitors of Ebola Virus Entry

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$600,000.00
Agency:
HHS
Principal Investigator:
Brett D. Welch – 801-587-1415
Abstract:
DESCRIPTION (provided by applicant): Ebola virus (EboV) is a filovirus that causes a highly deadly hemorrhagic fever in humans and non-human primates. Since its discovery in central Africa in 1976, there have been 16 natural human outbreaks with an averagemortality rate of 67%. There are no approved… More

CT-based Biomarker for Diagnosis of COPD Phenotypes and Disease Progression

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$145,269.00
Agency:
HHS
Principal Investigator:
Kirill Ostanin – 801-587-1456
Abstract:
DESCRIPTION (provided by applicant): Rheumatoid arthritis (RA) affects approximately 1.3 million adults in the United States and up to 1.5% of the population worldwide. In its progressive form the disease has debilitating effects including painful inflammation and destruction of the joints. This… More

Identification of novel small molecule inhibitors of Arf6 for the treatment of va

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$150,640.00
Agency:
HHS
Principal Investigator:
Kirill Ostanin – 801-587-1456
Abstract:
DESCRIPTION (provided by applicant): Age-Related Macular Degeneration is the most common cause of legal blindness in people over 60, affecting an estimated 1.6 million patients. Additionally, over 400,000 diabetic Americans are diagnosed each year with vision-threatening retinal edema and/or… More

Therapeutic D-peptide Inhibitor of HIV Entry

Award Year / Program / Phase:
2013 / SBIR / Phase II
Award Amount:
$3,000,000.00
Agency:
HHS
Principal Investigator:
Alan L. Mueller – 801-587-1426
Abstract:
DESCRIPTION (provided by applicant): With 33 million people living with HIV/AIDS (including 1.2 million in the US), and 1.8 million AIDS-related deaths annually, HIV/AIDS remains a formidable global epidemic (UNAIDS, CDC). Modern HIV therapy combines drugsfrom different classes to form cocktail … More